526 related articles for article (PubMed ID: 24478449)
1. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of the MicroScan NegCombo panel Type 44 for detection of extended-spectrum beta-lactamase among clinical isolates of Escherichia coli, Klebsiella species, and Proteus mirabilis].
Ko SY; Chung JW; Song AJ; Yoon NS; Sung H; Kim MN
Korean J Lab Med; 2009 Feb; 29(1):35-40. PubMed ID: 19262076
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the Phoenix automated microbiology system for detecting extended-spectrum beta-lactamase in Escherichia coli, Klebsiella species and Proteus mirabilis].
Lee KK; Kim ST; Hong KS; Huh HJ; Chae SL
Korean J Lab Med; 2008 Jun; 28(3):185-90. PubMed ID: 18594169
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
5. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
6. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca at the Radboud University Nijmegen Medical Centre in The Netherlands.
Sturm PD; Bochum ET; van Mook-Vermulst SV; Handgraaf C; Klaassen T; Melchers WJ
Microb Drug Resist; 2010 Mar; 16(1):55-60. PubMed ID: 20001741
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
[TBL] [Abstract][Full Text] [Related]
9. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
10. Predicament in Detection and Reporting of Extended Spectrum Beta Lactamase Production in Routine Antibiotic Susceptibility Testing.
Butt T; Raza S; Butt E
J Coll Physicians Surg Pak; 2017 Dec; 27(12):788-790. PubMed ID: 29185411
[TBL] [Abstract][Full Text] [Related]
11. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
12. Screening and confirmatory testing for extended spectrum beta-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates.
Hadziyannis E; Tuohy M; Thomas L; Procop GW; Washington JA; Hall GS
Diagn Microbiol Infect Dis; 2000 Feb; 36(2):113-7. PubMed ID: 10705053
[TBL] [Abstract][Full Text] [Related]
13. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
Zarakolu P; Metan G; Hasçelik G; Akova M
Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
[TBL] [Abstract][Full Text] [Related]
14. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.
Kohner PC; Robberts FJ; Cockerill FR; Patel R
J Clin Microbiol; 2009 Aug; 47(8):2419-25. PubMed ID: 19494061
[TBL] [Abstract][Full Text] [Related]
15. Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the Kinki region of Japan.
Yamasaki K; Komatsu M; Abe N; Fukuda S; Miyamoto Y; Higuchi T; Ono T; Nishio H; Sueyoshi N; Kida K; Satoh K; Toyokawa M; Nishi I; Sakamoto M; Akagi M; Nakai I; Kofuku T; Orita T; Wada Y; Jikimoto T; Kinoshita S; Miyamoto K; Hirai I; Yamamoto Y
J Clin Microbiol; 2010 Sep; 48(9):3267-73. PubMed ID: 20610688
[TBL] [Abstract][Full Text] [Related]
16. Multi-centre evaluation of a phenotypic extended spectrum β-lactamase detection guideline in the routine setting.
Platteel TN; Cohen Stuart JW; de Neeling AJ; Voets GM; Scharringa J; van de Sande N; Fluit AC; Bonten MJM; Leverstein-van Hall MA;
Clin Microbiol Infect; 2013 Jan; 19(1):70-76. PubMed ID: 22268620
[TBL] [Abstract][Full Text] [Related]
17. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
Jones CH; Tuckman M; Keeney D; Ruzin A; Bradford PA
Antimicrob Agents Chemother; 2009 Feb; 53(2):465-75. PubMed ID: 19015360
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital.
Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH
APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475
[TBL] [Abstract][Full Text] [Related]
19. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y
BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance.
Hansen DS; Schumacher H; Hansen F; Stegger M; Hertz FB; Schønning K; Justesen US; Frimodt-Møller N;
Scand J Infect Dis; 2012 Mar; 44(3):174-81. PubMed ID: 22364227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
